Category: ~$155M

  • PerkinElmer to Acquire Immunodiagnostic Systems Holdings for ~$155M

    Shots: PerkinElmer to acquire IDS in all cash transactions for ~$155M. The transaction is expected to be completed in Q3’21 The acquisition will allow PerkinElmer to foster its overall Diagnostics business and specifically its immunodiagnostics segment The acquisition will integrate PerkinElmer’s channel expertise and testing capabilities with IDS’ chemiluminescence products in endocrinology, autoimmunity, and infectious […]